Although several studies have converged upon reactivation of the MAPK pathway as a relevant mechanism of acquired resistance in melanoma [52–55], our findings indicate that increased compensatory signaling through the PI3K/AKT/mTOR axis might be generally more determinant in driving late-stage resistance. The gene discussed is MTOR; the disease is melanoma.